Minocycline in Stroke Study at Maimonides

Official title

Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial

Overview

The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale

Detailed description

Stroke is a major cause of death and disability in the United States. While treatments such as clot-busting drugs (tPA or TNK) and thrombectomy can help some patients with ischemic strokes, there are limited options for protecting the brain after a stroke. Minocycline is a low-cost antibiotic that may have protective effects on the brain due to its anti-inflammatory and neuroprotective properties.

At Maimonides Medical Center, we have used Minocycline for all eligible patients with acute strokes in clinical practice until March 2019, Studies found that Minocycline was associated with better stroke outcomes and lower death rates, especially in patients with moderate stroke severity. However, no large, randomized trial has yet confirmed its benefits.

This study will prospectively enroll 1,164 adults with moderate stroke (National Institutes of Health Stroke Scale 5-20) within 24 hours of symptom onset. Participants will be assigned by block randomization to receive either:

Minocycline 200 mg orally once daily for 5 days + standard stroke care, or Standard stroke care alone.

The study will measure stroke severity (using the \*NIHSS\*- National Institutes of Health Stroke Scale) and disability (using the mRS - \*modified Rankin Scale\*) at hospital discharge, 30 days, and 90 days. It will also monitor for death and any bleeding complications in the brain.

The goal is to see whether Minocycline, in addition to usual care, can safely improve recovery and survival in people with acute stroke. The results could help guide future stroke treatment nationwide.

NIHSS: \*National Institutes of Health Stroke Scale\*, is stroke severity scale, mRS: \*Modified Rankin Scale\*, is stroke disability scale, WHO: \*World Health Organization\*

Interventions

• Drug Minocycline 200mg
  Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.

Primary outcome measures

• Change in National Institutes of Health Stroke Scale (NIHSS) Score at Day 7 post stroke [Time frame: At day 7 after stroke onset]
• Change in National Institutes of Health Stroke Scale (NIHSS) Score at 90 days (+/- 7 days) post-stroke [Time frame: At 90 days (+/- 7 days) after stroke onset]

Secondary outcome measures (3)

• NIHSS Score at 30 Days Post-Stroke [Time frame: up to 30 days after stroke onset]
• Rate of Hemorrhagic Transformation of Ischemic Strokes [Time frame: 22-36 hours post treatment]
• All-Cause Mortality (mRS = 6) [Time frame: Up to 90 days (±7 days) after stroke onset]

Eligibility criteria

\* Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Age >/=18
• NIHSS 5-20 \*National Institutes of Health Stroke Scale\*
• Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \*(World Health Organization) \* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed
• The onset of neurological symptoms less than 24 hours

• Exclusion criteria

An individual who meets any of the following criteria is excluded from participation in this study:

• Clinically stroke is not suspected
• Allergic to the Tetracycline group of medications or Intolerance to Minocycline
• Pregnancy or suspected pregnancy or breastfeeding
• Previous history of intolerance to Minocycline
• Acute or chronic renal failure (stage III with GFR \*(Glomerular Filtration Rate) \* or Creatinine threshold)
• Any patients with contraindications to undergo CT (Computed Tomography) / MRI (Magnetic Resonance Imaging)
• Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission
• Pre-existing infectious disease requiring antibiotics
• Inability to tolerate enteral medications/feeds
• Patient/ family refusal

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

United States · 1 center

• Maimonides Medical Center — Brooklyn

Identifiers

NCT: NCT07237048 · 2024-05-01-MMC · Internal Stroke Research Funds

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗